Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ RIP3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA568522
Description
This target displays homology in the following species: Cow: 79%; Dog: 93%; Horse: 86%; Human: 100%; Mouse: 86%; Pig: 86%; Rat: 91%.
RIPK3 is a member of the receptor-interacting protein (RIP) family of serine/threonine protein kinases, which contains a C-terminal domain unique from other RIP family members. RIPK3 is predominantly localized to the cytoplasm, and specifically, are colocalized in the mitochondrion which can undergo nucleocytoplasmic shuttling dependent on novel nuclear localization and export signals. RIPK3 is a component of the tumor necrosis factor (TNF) receptor-I signaling complex, and can induce apoptosis and weakly activate the NF-kappaB transcription factor and caspase-8 prevents RIPK3-dependent necrosis without inducing apoptosis by functioning in a proteolytically active complex with CFLAR and that this complex is required for the protective function.
Specifications
RIP3 | |
Polyclonal | |
Unconjugated | |
RIPK3 | |
2610528K09Rik; AW107945; Hcyp2; Homocysteine respondent protein HCYP2; mRIP3; receptor interacting protein 3; receptor interacting serine/threonine kinase 3; receptor-interacting protein 3; receptor-interacting serine/threonine-protein kinase 3; receptor-interacting serine-threonine kinase 3; Rip3; RIP-3; Ripk3; RIP-like protein kinase 3 | |
Rabbit | |
Protein A | |
RUO | |
11035 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Immunohistochemistry, Western Blot | |
1 mg/mL | |
PBS with 2% sucrose and 0.09% sodium azide | |
Q9Y572 | |
RIPK3 | |
synthetic peptide directed towards the N terminal region of human RIP3. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction